REPARO NGF 0212: An 8-week phase I/II, multicenter, randomized, double-masked, vehicle controlled parallel group study with a 48 or 56 week open-label follow-up period to evaluate the safety and efficacy of two doses (10µg/ml and 20µg/ml) of recombinant human nerve growth factor eye drops solution versus vehicle in patients with Stage 2 and 3 of neurotrophic keratitis.